Owlet

Regulation And Tariffs Will Hinder Digital Health Yet Spur Recovery

AnalystLowTarget

Not Invested

Community Contributor

Published

16 Aug 25

Updated

15 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

171.2%

-21.4%

171.2%

-21.4%

You can edit this narrative until Dec 16 12:10 PM. Then, changes will post as Updates.

Author's Valuation

US$149.1% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 15 Dec 25

Fair value Increased 27%

OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile

Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.

AnalystLowTarget Fair Value

US$14

9.1% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

21.78%

Medical Equipment revenue growth rate

7.79%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.83%

Calculation

US$2.78m

Earnings '28

381.91x

PE Ratio '28

US$1.06b

Market Cap '28

US$1.06b

Market Cap '28

60.59m

No. shares '28

US$17.54

Share Price '28

US$17.54 Share Price '28

Discounted to 2025 @ 7.80% p.a.

US$14.00

Fair Value '25